Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives

Copyright © 2012 Wiley-VCH Verlag GmbH & Co. KGaA

Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives

Editor(s): Roland Kontermann

Published Online: 6 FEB 2012 04:44AM EST

Print ISBN: 9783527328499

Online ISBN: 9783527644827

DOI: 10.1002/9783527644827

About this Book

Product Information

About The Product

For this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The result is a comprehensive work covering all approaches and aspects of the topic in one handy volume, making this indispensable reading for companies and research institutions working on the development of biopharmaceuticals.

Table of contents

    1. You have free access to this content
      Front Matter (pages I–XVIII)

  2. Part One: General Information

    1. Chapter 1

      Half-Life Modulating Strategies–An Introduction (pages 1–21)

      Prof. Dr. Roland E. Kontermann

    2. Chapter 2

      Pharmacokinetics and Half-Life of Protein Therapeutics (pages 23–38)

      Bernd Meibohm

  3. Part Two: Half-Life Extension through Chemical and Post-Translational Modifications

    1. Chapter 3

      Half-Life Extension through PEGylation (pages 39–61)

      Simona Jevševar and Menči Kunstelj

    2. Chapter 4

      Half-Life Extension of Therapeutic Proteins via Genetic Fusion to Recombinant PEG Mimetics (pages 63–80)

      Uli Binder and Arne Skerra

    3. Chapter 5

      Half-Life Extension through O-Glycosylation (pages 81–94)

      Fuad Fares

    4. Chapter 6

      Polysialic Acid and Polysialylation to Modulate Antibody Pharmacokinetics (pages 95–115)

      Antony Constantinou, Chen Chen and Mahendra P. Deonarain

    5. Chapter 7

      Half-Life Extension through HESylation® (pages 117–140)

      Thomas Hey, Helmut Knoller and Peter Vorstheim

  4. Part Three: Half-Life Modulation Involving Recycling by the Neonatal Fc Receptor

    1. Chapter 8

      The Biology of the Neonatal Fc Receptor (FcRn) (pages 141–155)

      Jonghan Kim

    2. Chapter 9

      Half-Life Extension by Fusion to the Fc Region (pages 157–188)

      Jalal A. Jazayeri and Graeme J. Carroll

    3. Chapter 10

      Monomeric Fc Fusion Technology: An Approach to Create Long-Lasting Clotting Factors (pages 189–206)

      Jennifer A. Dumont, Xiaomei Jin, Robert T. Peters, Alvin Luk, Glenn F. Pierce and Alan J. Bitonti

    4. Chapter 11

      The Diverse Roles of FcRn: Implications for Antibody Engineering (pages 207–222)

      E. Sally Ward and Raimund J. Ober

    5. Chapter 12

      Half-Life Extension by Fusion to Recombinant Albumin (pages 223–247)

      Hubert J. Metzner, Thomas Weimer and Stefan Schulte

    6. Chapter 13

      AlbudAb™ Technology Platform–Versatile Albumin Binding Domains for the Development of Therapeutics with Tunable Half-Lives (pages 249–268)

      Christopher Herring and Oliver Schon

    7. Chapter 14

      Half-Life Extension by Binding to Albumin through an Albumin Binding Domain (pages 269–283)

      Fredrik Y. Frejd

    8. Chapter 15

      Half-Life Extension by Binding to Albumin through Small Molecules (pages 285–296)

      Sabrina Trüssel, Joerg Scheuermann and Dario Neri

  5. Part Four: Half-Life Extension with Pharmaceutical Formulations

    1. Chapter 16

      Half-Life Extension with Pharmaceutical Formulations: Liposomes (pages 297–314)

      Astrid Hartung and Gerd Bendas

    2. Chapter 17

      Half-Life Extension with Pharmaceutical Formulations: Nanoparticles by the Miniemulsion Process (pages 315–339)

      Katharina Landfester, Anna Musyanovych and Volker Mailänder

    1. You have free access to this content
      Index (pages 341–354)

SEARCH